参芪扶正注射液联合TP方案治疗晚期卵巢癌患者的疗效及对患者免疫功能的影响  

Efficacy of Shenqi Fuzheng injection combined with TP regimen in treatment of advanced ovarian cancer and its influence on immune function

作　　者：崔伟[1] 刘爱珍[1] 艾亮[2] 谢琼[3] 李文凯[3] 王长富 CUI Wei;LIU Ai-zhen;AI Liang;XIE Qiong;LI Wen-kai;WANG Chang-fu(Women&Infants Hospital of Zhengzhou,Zhengzhou450012,P.R.China)

机构地区：[1]郑州市妇幼保健院妇产科,河南郑州450012 [2]郑州市妇幼保健院检验科,河南郑州450012 [3]郑州市妇幼保健院影像科,河南郑州450012

出　　处：《中华肿瘤防治杂志》2020年第23期1927-1930,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的探讨参芪扶正注射液联合TP方案(紫杉醇+顺铂)治疗晚期卵巢癌患者的疗效及对患者免疫功能的影响。方法选取2013-03-17-2017-02-11郑州市妇幼保健院妇产科确诊的70例晚期卵巢癌患者作为研究对象,其中35例患者采用参芪扶正注射液+TP方案作为治疗组,平均年龄(44.3±5.1)岁,Ⅲ期14例,Ⅳ期21例;35例采用单纯TP方案治疗作为对照组,平均年龄(43.9±6.3)岁,Ⅲ期15例,Ⅳ期20例;两组患者均行4个周期化疗。比较两组患者近期疗效、骨髓抑制、不良反应情况以及T细胞亚群变化。结果治疗组总有效率为68.57%,高于对照组的42.86%,差异有统计学意义,χ2=4.69,P=0.03。对照组和治疗组均有不同程度的骨髓抑制,但治疗组WBC、Hb和PLT下降幅度低于对照组,治疗组不良反应发生率为20.00%,低于对照组的45.71%,χ2=5.25,P=0.02。治疗组患者治疗后生活质量改善率为91.43%,高于对照组的65.71%,差异有统计学意义,χ2=6.87,P=0.01。治疗后治疗组患者CD3+T、CD4+T和NK细胞比例及CD4+T/CD8+T分别为(47.91±6.28)%、(22.90±5.07)%、(15.13±3.53)%和0.80±0.13,对照组分别为(40.34±5.64)%、(17.90±6.94)%、(12.45±4.09)%和0.65±0.14,差异有统计学意义,P<0.01。Treg则在两组患者中均有所降低,治疗组和对照组分别为(10.36±4.46)%和(13.30±4.34)%,治疗组下降幅度更大,t=5.37,P<0.001。结论参芪扶正注射液联合TP方案可改善晚期卵巢癌患者生活质量,降低骨髓抑制和免疫抑制并减轻不良反应,延缓患者生存期。OBJECTIVE To investigate the efficacy of Shenqi Fuzheng injection combined with TP regimen in treatment of advanced ovarian cancer and its influence on immune function.METHODS Totally 70cases with ovarian cancer from 2013-03-17to 2017-02-11in Women&infants hosipital of Zhengzhou were selected and were divided into two groups:35cases using Shenqi Fuzheng injection combined with TP regimen(treatment group,mean age 44.3±5.1,14cases with stageⅢand 21cases with stageⅣ)and 35cases using TP regimen alone(control group,mean age 43.9±6.3,15cases with stageⅢand 20cases with stageⅣ),and these two groups underwent 4cycles of chemotherapy.The short-term curative effect,myelosuppression,adverse reaction and T lymphocyte subsets of the two groups were observed and compared.RESULTS The total effective rate of treatment group was statistically higher than that in control group(68.57%vs 42.86%,χ2=4.69,P=0.03).The two groups had different degrees of bone marrow suppression.The descending ranges of WBC,Hb and PLT for treatment group were lower than that of control group.In addition,the adverse reaction rate of treatment group was also lower than that of control group(20.00%vs 45.71%,χ2=5.25,P=0.02).The life quality improvement rate of treatment group after treatment was significantly higher than that of control group(91.43%vs 65.71%,χ2=6.87,P=0.01).CD3+T,CD4+T,CD4+T/CD8+T and NK of two groups after treatment were increased,while descending ranges of these cells in treatment group were lower than in control group[CD3+T:(47.91±6.28)%vs(40.34±5.64)%,t=3.62,P<0.01;CD4+T:(22.90±5.07)%vs(17.90±6.94)%,t=3.54,P<0.01;CD4+T/CD8+T:(0.80±0.13)vs(0.65±0.14),t=3.45,P<0.01;NK:(15.13±3.53)%vs(12.45±4.09)%,t=3.73,P<0.01].In addition,Treg in the treatment group and the control group were decreased obviously after treatment,and the descend range in treatment group was more significant[(10.36±4.46)%vs(13.30±4.34)%,t=5.37,P<0.001].CONCLUSION The combination of Shenqi Fuzheng injection and TP can improve the life quality of patient

关 键 词：晚期卵巢癌 参芪扶正注射液 TP方案 疗效 T细胞亚群 Treg 

分 类 号：R737.31[医药卫生—肿瘤]